Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Xenofon BaraliakosAtul A DeodharMaxime DougadosLianne S GenslerAnna MoltoJosef S SmolenAlan J KivitzDenis PoddubnyyMarga OortgiesenThomas VauxCarmen FleurinckJulie Shepherd-SmithChristine de la LogeNatasha de PeyrecaveDésirée van der HeijdePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
The safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The efficacy of bimekizumab in patients with AS was sustained through 3 years of treatment.